{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=192&agent_id=fda&agent_id=ema",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.026958,
    "timestamp_received": "2026-05-13T16:48:57.231905+00:00Z",
    "timestamp_returned": "2026-05-13T16:48:57.258863+00:00Z",
    "trace_id": "351fc77e-7c68-4371-ae7b-a45e112463ff"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 222,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.tibsovo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tibsovo (ivosidenib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Agios Pharmaceuticals, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tibsovo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "ivosidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 211192,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-10-24",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.tibsovo:3",
        "indication": "TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.",
        "initial_approval_date": "2021-08-25",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",
        "raw_biomarkers": "susceptible IDH1 mutation",
        "raw_cancer_type": "locally advanced or metastatic cholangiocarcinoma",
        "raw_therapeutics": "Tibsovo (ivosidenib)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.tibsovo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tibsovo (ivosidenib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Agios Pharmaceuticals, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tibsovo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "ivosidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 211192,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-10-24",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 192,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 76,
            "name": "IDH1 p.R132H",
            "genes": [
              {
                "id": 28,
                "name": "IDH1",
                "primaryCoding": {
                  "id": "hgnc:5382",
                  "code": "HGNC:5382",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000138413",
                      "code": "ENSG00000138413",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000138413"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3417",
                      "code": "3417",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3417"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_005896.4",
                      "code": "NM_005896.4",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "2q34"
                  },
                  {
                    "name": "location_sortable",
                    "value": "02q34"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "2"
              },
              {
                "name": "start_position",
                "value": 209113112
              },
              {
                "name": "end_position",
                "value": 209113112
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "T"
              },
              {
                "name": "cdna_change",
                "value": "c.395G>A"
              },
              {
                "name": "protein_change",
                "value": "p.R132H"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "4"
              },
              {
                "name": "rsid",
                "value": "rs121913500"
              },
              {
                "name": "hgvsg",
                "value": "2:g.209113112C>T"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 11,
          "conceptType": "Disease",
          "name": "Cholangiocarcinoma",
          "primaryCoding": {
            "id": "oncotree:CHOL",
            "code": "CHOL",
            "name": "Cholangiocarcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 92,
          "conceptType": "Drug",
          "name": "Ivosidenib",
          "primaryCoding": {
            "id": "ncit:C114383",
            "code": "C114383",
            "name": "Ivosidenib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2049873",
                "code": "2049873",
                "name": "ivosidenib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049873"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1560123",
                "code": "1560123",
                "name": "ivosidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1560123"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:773232006",
                "code": "773232006",
                "name": "Ivosidenib",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=773232006&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:36676369",
                "code": "36676369",
                "name": "Ivosidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/36676369"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "IDH1 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    },
    {
      "id": 972,
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
      "contributions": [
        {
          "id": 13,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema.tibsovo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tibsovo (ivosidenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo",
            "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Les Laboratoires Servier.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tibsovo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "ivosidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2023-05-12",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-01-15",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:ema.tibsovo:1",
        "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.",
        "initial_approval_date": "2023-05-04",
        "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/tibsovo-epar-public-assessment-report_en.pdf",
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "raw_biomarkers": null,
        "raw_cancer_type": "Cholangiocarcinoma",
        "raw_therapeutics": "Tibsovo (ivosidenib)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:ema.tibsovo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tibsovo (ivosidenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo",
            "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Les Laboratoires Servier.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tibsovo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "ivosidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2023-05-12",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-01-15",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 192,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 76,
            "name": "IDH1 p.R132H",
            "genes": [
              {
                "id": 28,
                "name": "IDH1",
                "primaryCoding": {
                  "id": "hgnc:5382",
                  "code": "HGNC:5382",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000138413",
                      "code": "ENSG00000138413",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000138413"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3417",
                      "code": "3417",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3417"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_005896.4",
                      "code": "NM_005896.4",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "2q34"
                  },
                  {
                    "name": "location_sortable",
                    "value": "02q34"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "2"
              },
              {
                "name": "start_position",
                "value": 209113112
              },
              {
                "name": "end_position",
                "value": 209113112
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "T"
              },
              {
                "name": "cdna_change",
                "value": "c.395G>A"
              },
              {
                "name": "protein_change",
                "value": "p.R132H"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "4"
              },
              {
                "name": "rsid",
                "value": "rs121913500"
              },
              {
                "name": "hgvsg",
                "value": "2:g.209113112C>T"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 11,
          "conceptType": "Disease",
          "name": "Cholangiocarcinoma",
          "primaryCoding": {
            "id": "oncotree:CHOL",
            "code": "CHOL",
            "name": "Cholangiocarcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 92,
          "conceptType": "Drug",
          "name": "Ivosidenib",
          "primaryCoding": {
            "id": "ncit:C114383",
            "code": "C114383",
            "name": "Ivosidenib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2049873",
                "code": "2049873",
                "name": "ivosidenib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049873"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1560123",
                "code": "1560123",
                "name": "ivosidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1560123"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:773232006",
                "code": "773232006",
                "name": "Ivosidenib",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=773232006&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:36676369",
                "code": "36676369",
                "name": "Ivosidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/36676369"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "IDH1 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    }
  ]
}